4EGI-1 is the prototype of a novel class of anticancer agents targeting translation. Patented drug-like
analogue 1 was synthesized and examined for inhibition of translation and cytotoxicity in cancer cells.
Unexpectedly, 1 was found inactive in both assays.
Keywords: Cancer, eIF4E, metastatic melanoma, mRNA translation, protein synthesis, thiazoles.
Rights & PermissionsPrintExport